RAPT Therapeutics Inc.: Positive Study Data, $250 Million Capital Increase, and Guggenheim Sees 130% Price Potential
Reading Time: 4 minutes
RAPT Therapeutics Inc. (RAPT) is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapies for patients with inflammatory and immunological diseases as well as cancer. The company leverages deep and proprietary expertise in immunology to develop therapeutic molecules aimed at modulating the critical immune responses underlying these diseases. Central to the approach is the development of orally available small molecule therapies. This mode of administration offers potential advantages...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
